Drug Trial Radar · NCT03896633
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
Last checked: Nov 20, 2026Latest source record: May 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
637
Actual
Start
Feb 28, 2018
Primary completion
Nov 17, 2018
Study completion Nov 17, 2018
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM
Conditions
- Glaucoma
- Open Angle or Ocular Hypertension
Interventions
brinzolamide 1% ophthalmic suspensionDrug
brinzolamide 1% ophthalmic suspension
Azopt 1%Drug
Azopt 1%, RLD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular Pressure (IOP)Time frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Various
Bridgewater, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.